Contact

• workRoom C50 Biodiscovery Institute 1,2
  University Park
  Nottingham
  NG7 2RD
  UK
• Mostafa.Mohamed@nottingham.ac.uk

Biography

I completed my Master's degree in Medicinal Chemistry at Faculty of Pharmacy, Assiut University. The work lies on the In Silico design and synthesis of small molecules as inhibitors of cell cycle checkpoints (as CDK2) with anticancer activities. In 2022, I started my PhD in Biomolecular Sciences and Medicinal Chemistry, School of Pharmacy, University of Nottingham.

Expertise Summary

My expertise includes In Silico drug design, synthetic chemistry, and biophysical and biochemical techniques.

Research Summary

Current research include:

• Design of small compounds as inhibitor proteases in the ubiquitin pathway
• Chemical synthesis of small molecules
• Establishing protein structure and characterizing protein-ligand interactions

Recent Publications

• WESAM S. QAYED, MOSTAFA A. HASSAN, AHMED MEGAHED ABOUWARDA, YASSER MUSA IBRAHIM and TAREK ABOUL-FADL, 2023. Computational Design of Azine-Linked Hybrids of 2-Indolinone-Thiazolodine Scaffold as Novel and Promising Quorum Sensing Inhibitors Polycyclic Aromatic Compounds.
• WESAM S. QAYED, MOSTAFA A. HASSAN, WAEL M. EL-SAYED, JOSE ROGERIO A. SILVA and TAREK ABOUL-FADL, 2022. Novel Azine Linked Hybrids of 2-Indolinone and Thiazolodinone Scaffolds as CDK2 Inhibitors with Potential Anticancer Activity: In Silico Design, Synthesis, Biological, Molecular Dynamics and Binding Free Energy Studies Bioorganic Chemistry. 126(105884),
• TAREK ABOUL-FADL, MOSTAFA A. HASSAN, WESAM S. QAYED and WAEL M. EL-SAYED, 2021. Novel 2-Indolinone Based derivatives Targeting Cell Cycle Checkpoint’s Proteins as Potential Anticancer Agents In: 2nd Global Virtual Conference on Pharmaceutical Sciences and Drug Development.
• TAREK ABOUL-FADL, AHMED S. M. ABORAIA, ABU-BAKER M. ABDEL-AAL, MOHAMMED K. ABDEL-HAMID, WESAM S. QAYED, OLA M. F. ABOU-GHADIR, MARIAM E. I. ABDEL-RASOUL, RANA M. IBRAHIM, MOSTAFA A. HASSAN, NOHA G. M. FEKRY, HEND A.A. ABD EL-WAHAB and ADEL F. YOUSSEF, 2018. Modified Lidocaine Derivatives as a Potential Inhibitors of Eosinophils In: 2nd International Congress and Exhibition on Pharmacy (Pharmacy-2018), Paris, Farnce, August 20-21, 2018.

• View all publications

• WESAM S. QAYED, MOSTAFA A. HASSAN, AHMED MEGAHED ABOUWARDA, YASSER MUSA IBRAHIM and TAREK ABOUL-FADL, 2023. Computational Design of Azine-Linked Hybrids of 2-Indolinone-Thiazolodine Scaffold as Novel and Promising Quorum Sensing Inhibitors Polycyclic Aromatic Compounds.
• WESAM S. QAYED, MOSTAFA A. HASSAN, WAEL M. EL-SAYED, JOSE ROGERIO A. SILVA and TAREK ABOUL-FADL, 2022. Novel Azine Linked Hybrids of 2-Indolinone and Thiazolodinone Scaffolds as CDK2 Inhibitors with Potential Anticancer Activity: In Silico Design, Synthesis, Biological, Molecular Dynamics and Binding Free Energy Studies Bioorganic Chemistry. 126(105884),
• TAREK ABOUL-FADL, MOSTAFA A. HASSAN, WESAM S. QAYED and WAEL M. EL-SAYED, 2021. Novel 2-Indolinone Based derivatives Targeting Cell Cycle Checkpoint’s Proteins as Potential Anticancer Agents In: 2nd Global Virtual Conference on Pharmaceutical Sciences and Drug Development.
• TAREK ABOUL-FADL, AHMED S. M. ABORAIA, ABU-BAKER M. ABDEL-AAL, MOHAMMED K. ABDEL-HAMID, WESAM S. QAYED, OLA M. F. ABOU-GHADIR, MARIAM E. I. ABDEL-RASOUL, RANA M. IBRAHIM, MOSTAFA A. HASSAN, NOHA G. M. FEKRY, HEND A.A. ABD EL-WAHAB and ADEL F. YOUSSEF, 2018. Modified Lidocaine Derivatives as a Potential Inhibitors of Eosinophils In: 2nd International Congress and Exhibition on Pharmacy (Pharmacy-2018), Paris, Farnce, August 20-21, 2018.
• TAREK ABOUL-FADL, AHMED S. M. ABORAIA, ABU-BAKER M. ABDEL-AAL, MOHAMMED K. ABDEL-HAMID, WESAM S. QAYED, OLA M. F. ABOU-GHADIR, RANA M. IBRAHIM, MARIAM E. I. ABDEL-RASOUL, MOSTAFA A. HASSAN, NOHA G. M. FEKRY, HEND A.A. ABD EL-WAHAB and ADEL F. YOUSSEF, 2017. Novel synthetic inhibitors of eosinophils with potential anti-asthmatic activity In: 4th International Congress on Drug Discovery, Designing and Development, Chicago, Illinois, USA, November 2-3, 2017.